Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Mar 12, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to compare two treatments for patients with liver cirrhosis who have a condition called portal vein thrombosis (PVT). PVT occurs when a blood clot blocks the portal vein, which carries blood to the liver. The trial will evaluate the effectiveness of nadroparin, a type of blood thinner, against a procedure called transjugular intrahepatic portosystemic shunt (TIPS) in patients who do not have symptoms but whose condition has not improved with other treatments.

To take part in the study, participants must be diagnosed with liver cirrhosis and have a significant blockage in their portal vein, as confirmed by a specific imaging test. They should also be between the ages of 18 and 75 and be willing to sign a consent form. However, individuals with certain health issues, such as severe liver problems, active bleeding, or specific allergies, will not be eligible. While this trial is not yet recruiting participants, those who join can expect careful monitoring and support as they receive one of the two treatments being studied.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with liver cirrhosis
• • Diagnosis of portal vein thrombosis through computed tomographic venography with a thrombus diameter exceeding 30% of the vessel diameter.
• • Consent to participate in the clinical trial and the signing of an informed consent form.
• Exclusion Criteria:
• • Presence of acute symptoms such as fever, abdominal pain or bleeding, or of cavernous transformation
• • Patients with Child-Pugh C.
• • Pregnant or lactating women.
• • With a history of liver cancer or other malignancy.
• • Severe heart, lung diseases, or significant renal dysfunction.
• • Allergies to anticoagulant medications, uncontrolled hypertension, history of cerebral hemorrhage, discovery of gastrointestinal ulcers, ulcerative colitis, subacute bacterial endocarditis, or other contraindications to anticoagulant drugs.
• • On concomitant therapy of immunosuppressive drugs.
• • With coagulation disorders other than liver disease.
• • With active variceal bleeding.